Fetal Bovine Serum Market Size & Share 2026-2035

Fetal Bovine Serum Market Size

The global fetal bovine serum market was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.2 billion in 2026 to USD 2.3 billion by 2035, expanding at a CAGR of 7.4%, according to the latest report published by Global Market Insights Inc.

This substantial growth is driven by numerous factors, such as increasing research activities in the biopharmaceutical and biotechnological fields, increasing prevalence of acute and chronic diseases, and rising demand for vaccine production. Fetal bovine serum (FBS) is a nutrient-rich biological supplement derived from the blood of bovine fetuses and widely used in cell culture applications. It contains essential growth factors, hormones, proteins, and vitamins that support cell growth and proliferation. FBS is commonly used in research, biopharmaceutical production, and vaccine development due to its ability to maintain cell viability and functionality.

Leading companies in the fetal bovine serum market include Thermo Fisher Scientific, Inc., Merck KGaA, Cytiva, Corning Incorporated, and PAN-Biotech. These companies are expanding their market presence by enhancing serum processing technologies, strengthening quality assurance and traceability systems, investing in advanced filtration and purification methods, and increasing production capacity.

The market has increased from USD 801.3 million in 2022 and reached USD 1 billion in 2024, with a historic growth rate of 12.1%. Increasing research activities across the biopharmaceutical and biotechnology sectors represent a key driver for the growth of the fetal bovine serum (FBS) market. FBS is a critical supplement widely used in cell culture applications due to its rich composition of growth factors, hormones, and nutrients that support cell proliferation and viability. As investments in drug discovery, vaccine development, regenerative medicine, and biologics manufacturing continue to rise, the demand for reliable and high-quality cell culture media components such as FBS has grown significantly. Academic institutions, contract research organizations (CROs), and biopharma companies are intensifying efforts in areas such as cancer research, stem cell therapy, and monoclonal antibody production, all of which rely heavily on cell-based assays and culture systems.

Additionally, the expansion of personalized medicine and advanced therapies has further increased the need for consistent and contamination-free serum products. Emerging economies are also witnessing a surge in life sciences research funding, contributing to broader market demand. Overall, the increasing scale and complexity of biomedical research activities are directly propelling the adoption of FBS, reinforcing its essential role in modern biotechnological advancements.

Additionally, the rising demand for vaccine production is a significant driver for the fetal bovine serum (FBS) market. Increasing global immunization programs, along with the need to address emerging and re-emerging infectious diseases, have accelerated vaccine development and manufacturing activities. FBS plays a critical role in supporting the growth of cell cultures used in viral propagation and antigen production, making it an essential component in vaccine manufacturing processes. Additionally, the expansion of large-scale vaccine production facilities and investments in pandemic preparedness are further strengthening demand for high-quality serum products. Biopharmaceutical companies are increasingly focusing on improving production efficiency and scalability, which depends on reliable and consistent cell culture inputs such as FBS. Furthermore, ongoing advancements in vaccine technologies, including recombinant and cell-based vaccines, are expected to sustain long-term demand for fetal bovine serum across global markets.

Fetal Bovine Serum Market Trends

• The increasing prevalence of acute and chronic diseases is a significant driver for the fetal bovine serum (FBS) market. Rising incidences of conditions such as cancer, cardiovascular diseases, diabetes, and infectious diseases have intensified the need for advanced biomedical research and therapeutic development. FBS is a crucial component in cell culture processes, enabling researchers to study disease mechanisms and develop effective treatments.
• Additionally, the growing global disease burden has substantially increased the demand for vaccines. FBS is widely used in vaccine production as it supports the growth of cells required for viral propagation and antigen development. As immunization programs expand worldwide to combat both emerging and existing diseases, the reliance on high-quality serum products continues to rise.
• Furthermore, increased focus on chronic disease management and regenerative medicine is driving the adoption of cell-based research, where FBS plays a key supporting role. These applications require consistent, nutrient-rich environments, thereby boosting the demand for reliable serum solutions.
• According to the World Health Organization (WHO), the global vaccine market reached approximately seven billion doses in 2023, with an estimated financial value of US$ 77 billion. This large-scale vaccine production underscores the critical role of FBS in supporting expanding biopharmaceutical and immunization efforts.

Fetal Bovine Serum Market Analysis

Based on the product type, the fetal bovine serum market is segmented into stem cell, charcoal stripped, exosome depleted, dialyzed fetal bovine serum, chromatographic, and other product. The stem cell segment held the largest industry share of 29.5% in 2025.

• Stem cell fetal bovine serum accounted for the dominant share within the product type segment, driven by its extensive utilization in stem cell research and regenerative medicine applications. This type of serum is specially processed to support the growth, proliferation, and maintenance of pluripotent and multipotent stem cells. The increasing focus on cell-based therapies, tissue engineering, and personalized medicine has reinforced the need for optimized culture conditions, thereby supporting segment expansion.
• Additionally, advancements in clinical research involving induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) continue to create sustained demand for high-quality, application-specific FBS products.
• The charcoal stripped segment accounted for USD 212.3 million in 2025 and is projected to expand at a CAGR of 8.7% from 2026 to 2035. Charcoal stripped fetal bovine serum is widely used in hormone-sensitive studies due to its reduced levels of endogenous hormones, lipids, and growth factors. This product is particularly critical in endocrine research and receptor-binding assays where controlled experimental conditions are required. Furthermore, its application in cancer research, especially hormone-dependent cancer models, enhances its importance in laboratory settings. The growing need for precise and reproducible experimental outcomes is supporting the demand for charcoal stripped variants across pharmaceutical and academic research environments.
• The exosome depleted segment accounted for USD 189.7 million in 2025 and is projected to expand at a CAGR of 8.4% from 2026 to 2035. Exosome depleted fetal bovine serum is gaining traction as exosome research continues to expand across diagnostics and therapeutic development. This serum type undergoes specialized processing to remove extracellular vesicles, ensuring minimal interference in downstream applications. Moreover, its usage in biomarker discovery, drug delivery studies, and cell signalling research contributes to its increasing adoption. The rise in interest in extracellular vesicle-based research frameworks is expected to sustain steady demand for this segment.
• The dialyzed fetal bovine serum segment accounted for USD 155 million in 2025 and is projected to expand at a CAGR of 7.9% from 2026 to 2035. Dialyzed fetal bovine serum is utilized in applications requiring the removal of low molecular weight components such as salts, amino acids, and small metabolites. This makes it highly suitable for metabolic studies and controlled cell culture experiments. Additionally, it plays a critical role in bioprocess optimization and protein expression studies where defined nutrient conditions are essential. The increasing emphasis on precision-driven research methodologies is further supporting the adoption of dialyzed serum products.

Based on the application, the fetal bovine serum market is classified into cell culture media, human and animal vaccine production, drug discovery, cell-based research, and other applications. The cell culture media segment led with a market size of USD 330.9 million in 2025.

• The cell culture media segment accounted for the leading share in the fetal bovine serum market. The widespread use of FBS as a critical supplement in media formulations, providing essential growth factors and nutrients, supports its extensive utilization. Additionally, increasing demand for reliable and reproducible cell culture systems in research and biopharmaceutical manufacturing continues to drive segment growth. Furthermore, advancements in cell-based technologies and expansion of bioproduction activities are reinforcing the need for high-quality serum in maintaining optimal cell growth conditions.
• The human and animal vaccine production segment accounted for USD 284.2 million in 2025 and is projected to expand at a CAGR of 8.1% from 2026 to 2035. The human and animal vaccine production segment is driven by the increasing need for effective immunization programs and expanding vaccine manufacturing capabilities. FBS plays a vital role in supporting cell culture processes required for viral cultivation and antigen production. Moreover, rising efforts toward pandemic preparedness and routine vaccination programs are strengthening demand for serum-based inputs. The expansion of veterinary vaccines further contributes to steady adoption within this segment.
• The drug discovery segment accounted for USD 184.8 million in 2025 and is projected to expand at a CAGR of 6% from 2026 to 2035. The drug discovery segment utilizes fetal bovine serum extensively in preclinical research and compound screening. FBS supports cell viability and assay performance, enabling accurate evaluation of drug efficacy and toxicity. Additionally, increasing investment in novel therapeutics and biologics development is driving the use of advanced in vitro models. Furthermore, the need for consistent experimental outcomes is encouraging the use of standardized and high-quality serum products in research workflows.
• The cell-based research segment accounted for USD 192.2 million in 2025 and is projected to expand at a CAGR of 8.6% from 2026 to 2035. Cell-based research represents a key application area supported by growing interest in disease modeling, stem cell studies, and regenerative medicine. FBS is essential for maintaining cell proliferation and functionality in laboratory environments. Moreover, increasing academic and industrial collaborations are expanding research activities across various therapeutic areas. The rising focus on precision medicine and cellular therapies is further supporting demand for serum in experimental applications.

Based on the end-user, the fetal bovine serum market is fragmented into biotechnology and pharmaceutical industries, research and academic institutes, diagnostic labs, and other end-users. The biotechnology and pharmaceutical industries segment is expected to reach USD 961.1 million by the end of 2035.

• The biotechnology and pharmaceutical industries segment accounted for the leading share in the fetal bovine serum market. The extensive use of FBS in drug discovery, biologics production, vaccine development, and cell-based assays support its strong adoption across this segment. Additionally, increasing investments in biologics and advanced therapies are driving demand for high-quality, consistent serum products.
• Furthermore, the need for reproducibility and regulatory compliance in manufacturing processes continues to strengthen the reliance on certified FBS solutions.
• The research and academic institutes segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 7% over the forecast period. Research and academic institutes represent a significant end-user segment, driven by growing life sciences research activities. FBS is widely used in cell culture studies, disease modelling, and experimental biology applications. Moreover, increasing funding for biomedical research and collaborations with industry participants are supporting the adoption of serum products. The continuous expansion of laboratory infrastructure further contributes to sustained demand.
• The diagnostic laboratories segment accounted for USD 140.2 million in 2025 and is projected to expand at a CAGR of 8.8% from 2026 to 2035. Diagnostic laboratories utilize fetal bovine serum in assay development, quality control, and diagnostic testing applications. Additionally, the growing demand for advanced diagnostic solutions and precision testing is supporting the use of cell-based assays. Furthermore, increasing focus on early disease detection and monitoring is contributing to the steady integration of FBS in laboratory workflows

North America Fetal Bovine Serum Market

The North America region accounted for 38.2% of the global fetal bovine serum market in 2025. The fetal bovine serum market in North America is experiencing robust expansion.

• The U.S. market was valued at USD 277.8 million and USD 313.3 million in 2022 and 2023, respectively. The market size reached USD 387.6 million in 2025, growing from USD 349.2 million in 2024, and is anticipated to grow at a CAGR of 7% from 2026 to 2035.
• The increasing prevalence of acute and chronic diseases in North America serves as a key driver for the fetal bovine serum (FBS) market. The rising incidence of conditions such as cancer, cardiovascular diseases, diabetes, and infectious disorders has accelerated the need for advanced research, drug development, and therapeutic innovation. FBS plays a critical role in cell culture processes used extensively in disease modeling, toxicity testing, and the development of biologics and vaccines.
• Additionally, the growing burden of chronic conditions has led to increased investment in biomedical research and clinical studies, further strengthening demand for high-quality serum products.
• The region’s strong focus on precision medicine and regenerative therapies continues to support the adoption of FBS in both research and biopharmaceutical production environments.

Europe Fetal Bovine Serum Market

Europe fetal bovine serum market accounted for USD 316.5 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• The expansion of academic and clinical research activities is a key driver for the market in Europe. Increasing focus on cell-based therapies and advanced biologics development is driving the demand for FBS in laboratory and clinical settings.
• Additionally, strong regulatory frameworks and quality assurance standards are encouraging the adoption of certified and ethically sourced serum products. This is enhancing product reliability and consistency across applications.
• Furthermore, the presence of established biopharmaceutical manufacturers and research collaborations is supporting innovation in cell culture technologies. Increasing funding for life sciences research is contributing to sustained market growth.
• Growing emphasis on vaccine development and immunology research is also reinforcing the need for high-performance serum products across the region.

Asia Pacific Fetal Bovine Serum Market

The Asia Pacific region is projected to show a lucrative growth of about 8% during the forecast period.

• The expansion of vaccine production in Asia Pacific is significantly driving the fetal bovine serum (FBS) market. The region has emerged as a key manufacturing hub, supported by increasing government initiatives and investments in immunization programs. Countries such as India and China are scaling up vaccine production capabilities to address both regional and global demand, thereby increasing the need for cell culture components, including FBS.
• Additionally, the growing emphasis on pandemic preparedness and routine vaccination programs is accelerating research and production activities. FBS plays a vital role in supporting cell growth and viral propagation during vaccine development processes. As a result, biopharmaceutical manufacturers are increasingly relying on high-quality serum products to ensure efficiency and consistency in production.
• Furthermore, the strong growth of the vaccine industry in the region reinforces market expansion. For instance, the vaccines market in India is projected to reach a revenue of US$ 1.08 billion in 2026, highlighting the increasing scale of production activities. This rising market value reflects the growing demand for vaccine-related inputs, thereby supporting sustained adoption of fetal bovine serum across Asia Pacific

Latin America Fetal Bovine Serum Market 

The Latin America fetal bovine serum market is experiencing robust growth over the analysis timeframe.

• The expansion of the pharmaceutical and biotechnology sectors is a major factor driving the fetal bovine serum market in Latin America. Increasing research initiatives and local drug development activities are contributing to rising demand for cell culture media.
• Additionally, improvements in laboratory infrastructure and research capabilities are supporting the adoption of advanced cell culture techniques. This is increasing reliance on serum-based supplements for experimental consistency.
• Furthermore, growing focus on vaccine production and public health initiatives is driving the requirement for FBS in biologics development. Regional efforts to strengthen healthcare systems are contributing to higher product usage.
• Increasing collaborations with international research organizations are also enhancing access to advanced technologies, further supporting market growth.

Middle East and Africa Fetal Bovine Serum Market 

The Middle East and Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• Increasing investment in healthcare and life sciences research is playing a critical role in driving the FBS market in the Middle East and Africa. The development of modern laboratory facilities is supporting the adoption of cell culture-based research practices.
• Additionally, rising focus on infectious disease research and vaccine development is contributing to increased demand for serum products. This is particularly relevant in addressing region-specific disease challenges.
• Furthermore, the expansion of academic research institutions and biotechnology initiatives is strengthening the use of FBS in experimental and clinical applications.
• Growing efforts to build research capabilities and improve scientific infrastructure are supporting long-term market development, alongside increasing awareness regarding advanced therapeutic research approaches.

Fetal Bovine Serum Market Share

• The top five players, Thermo Fisher Scientific, Inc., Merck KGaA, Cytiva, Corning Incorporated, and PAN-Biotech, collectively accounted for a 50% share of the global fetal bovine serum market, driven by strong capabilities in high-quality serum production, advanced processing and filtration technologies, extensive distribution networks, and increasing adoption of cell culture solutions across biopharmaceutical research, vaccine manufacturing, and regenerative medicine applications across key regions.
• Fetal bovine serum (FBS) manufacturers, biotechnology companies, and research institutions are increasingly focusing on technological advancements and quality optimization to enhance cell culture performance and reliability. Key areas of emphasis include improved serum processing techniques, filtration technologies, and lot-to-lot consistency to ensure reproducibility in research outcomes. Additionally, advancements in contamination control, traceability systems, and serum characterization are supporting higher product standards. Continuous investments in automation, cold chain logistics, and advanced storage solutions are ensuring the stability and integrity of FBS across biopharmaceutical production facilities and laboratories.
• Market participants, including biopharmaceutical companies, academic institutions, and contract research organizations, are strengthening strategic collaborations to expand access to high-quality fetal bovine serum and support its application in research and manufacturing. Partnerships with slaughterhouses and certified suppliers are improving raw material sourcing and traceability. Moreover, collaborations with biotechnology firms and research institutes are supporting innovation in serum alternatives and optimized cell culture media. These initiatives enhance supply chain efficiency, improve product availability, and promote the adoption of FBS across drug development, vaccine production, and regenerative medicine applications, contributing significantly to overall market growth.

Fetal Bovine Serum Market Companies

Few of the prominent players operating in the fetal bovine serum industry include:

• Atlas Biologicals, Inc.
• BioIVT
• Bio-Techne
• Biowest (Sera Scandia A/S)
• Corning Incorporated
• Cytiva
• Gemini Bio-Products
• HiMedia Laboratories Pvt Ltd
• Merck KGaA
• MP Biomedicals
• PAN-Biotech
• Rocky Mountain Biologicals (RMBIO)
• TCS Biosciences
• Thermo Fisher Scientific, Inc.
• ZenBio, Inc.

• Corning incorporated

Corning strengthens its position through its integrated cell culture solutions, including FBS products designed for reproducibility, supporting high-throughput research and consistent laboratory performance.

• PAN- Biotech

PAN-Biotech strengthens its position through diverse FBS offerings, emphasizing quality control and application-specific solutions to support research, diagnostics, and biopharmaceutical production needs.

Fetal Bovine Serum Market News:

• In April 2021, Thermo Fisher Scientific Inc. announced a definitive agreement of acquisition of Pharmaceutical Product Development, Inc (PPD). This acquisition helped in enhancing its research and development activities which contributed to the developing demand of fetal bovine serum.

The fetal bovine serum market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Stem cell
• Charcoal stripped
• Exosome depleted
• Dialyzed fetal bovine serum
• Chromatographic
• Other product types

Market, By Application

• Cell culture media
• Human and animal vaccine production
• Drug discovery
• Cell based research
• Other applications

Market, By End use

• Biotechnology and pharmaceutical industries
• Research and academic institutes
• Diagnostic labs
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE